Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-
Clinical Trials
Related News

Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma

First Posted Date
2023-10-30
Last Posted Date
2023-11-22
Lead Sponsor
Xuekui Liu
Target Recruit Count
52
Registration Number
NCT06107114
Locations
🇨🇳

Sun Yat-sen University, Guangzhou, Guangdong, China

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

First Posted Date
2023-10-26
Last Posted Date
2023-10-30
Lead Sponsor
Beijing Tongren Hospital
Target Recruit Count
272
Registration Number
NCT06102395
Locations
🇨🇳

Beijing Tongren Hospital, Beijing, Beijing, China

Preoperative Hypofractionated Radiotherapy with FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

First Posted Date
2023-10-12
Last Posted Date
2024-10-02
Lead Sponsor
Mayo Clinic
Target Recruit Count
99
Registration Number
NCT06078709
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

First Posted Date
2023-10-10
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
556
Registration Number
NCT06074588
Locations
🇧🇷

A. C. Camargo Cancer Center-CAPEC ( Site 0442), Sao Paulo, Brazil

🇧🇷

Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0446), Sao Paulo, Brazil

🇨🇱

K2 Oncology ( Site 0514), Santiago, Region M. De Santiago, Chile

and more 165 locations

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Phase 2
Active, not recruiting
Conditions
Prostate Cancer
Interventions
Drug: Docetaxel
Drug: ADT
Drug: Abiraterone
First Posted Date
2023-09-29
Last Posted Date
2024-05-07
Lead Sponsor
Northwestern University
Target Recruit Count
150
Registration Number
NCT06060587
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

First Posted Date
2023-09-21
Last Posted Date
2024-10-23
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
57
Registration Number
NCT06046482
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

First Posted Date
2023-09-18
Last Posted Date
2024-10-02
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
174
Registration Number
NCT06042569
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

First Posted Date
2023-09-08
Last Posted Date
2023-09-08
Lead Sponsor
Ukrainian Society of Clinical Oncology
Target Recruit Count
758
Registration Number
NCT06028737
Locations
🇺🇦

National Cancer Institute, Kyiv, Ukraine

A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

First Posted Date
2023-09-08
Last Posted Date
2024-12-04
Lead Sponsor
BeiGene
Target Recruit Count
100
Registration Number
NCT06029127
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China

🇨🇳

Gansu Provincial Hospital, Lanzhou, Gansu, China

and more 15 locations

Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma

First Posted Date
2023-09-05
Last Posted Date
2023-09-05
Lead Sponsor
Xuekui Liu
Target Recruit Count
30
Registration Number
NCT06023875
Locations
🇨🇳

Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy